Keelan Byrne

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Does stereotactic ablative body radiotherapy (SABR) added to continued systemic therapy improve time to treatment failure compared with physician's choice of systemic therapy in oligoprogressive ER-positive, HER2-negative advanced breast cancer? Study protocol for a multicentre, randomised, open-label phase II trial in Australian tertiary cancer centres (AVATAR-II).

Does stereotactic ablative body radiotherapy (SABR) added to continued systemic therapy improve time to treatment failure compared with physician's choice of systemic therapy in oligoprogressive ER-positive, HER2-negative advanced breast cancer? Study protocol for a multicentre, randomised, open-label phase II trial in Australian tertiary cancer centres (AVATAR-II).

Journal: BMJ open

Published: September 03, 2026

Acute Toxicity With Trastuzumab Emtansine and Concurrent Radiotherapy: Non-Consecutive Case Series.

Acute Toxicity With Trastuzumab Emtansine and Concurrent Radiotherapy: Non-Consecutive Case Series.

Journal: Asia-Pacific journal of clinical oncology

Published: September 17, 2025

Case Report: Serial stereotactic radiotherapy in lieu of systemic therapy change for oligoprogressive breast cancer: eight courses to 17 metastases.

Case Report: Serial stereotactic radiotherapy in lieu of systemic therapy change for oligoprogressive breast cancer: eight courses to 17 metastases.

Journal: Frontiers in oncology

Published: June 05, 2025

Technical feasibility of delivering a simultaneous integrated boost in partial breast irradiation.

Technical feasibility of delivering a simultaneous integrated boost in partial breast irradiation.

Journal: Physics and imaging in radiation oncology

Published: June 03, 2024

Survival outcomes for women with a solitary extracranial metastasis from breast cancer.

Survival outcomes for women with a solitary extracranial metastasis from breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: November 26, 2023

The HI-FIVE Trial: A Prospective Trial Using 4-Dimensional 68Ga Ventilation-Perfusion Positron Emission Tomography-Computed Tomography for Functional Lung Avoidance in Locally Advanced Non-small Cell Lung Cancer.

The HI-FIVE Trial: A Prospective Trial Using 4-Dimensional 68Ga Ventilation-Perfusion Positron Emission Tomography-Computed Tomography for Functional Lung Avoidance in Locally Advanced Non-small Cell Lung Cancer.

Journal: International journal of radiation oncology, biology, physics

Published: November 29, 2022

Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for Oligometastases.

Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for Oligometastases.

Journal: International journal of radiation oncology, biology, physics

Published: March 15, 2022

Increasing use of post-mastectomy hypofractionated radiation therapy for breast cancer in Victoria.

Increasing use of post-mastectomy hypofractionated radiation therapy for breast cancer in Victoria.

Journal: Journal of medical imaging and radiation oncology

Published: July 17, 2021

Single-arm prospective interventional study assessing feasibility of using gallium-68 ventilation and perfusion PET/CT to avoid functional lung in patients with stage III non-small cell lung cancer.

Single-arm prospective interventional study assessing feasibility of using gallium-68 ventilation and perfusion PET/CT to avoid functional lung in patients with stage III non-small cell lung cancer.

Journal: BMJ open

Published: December 11, 2020

Safety, Efficacy, and Patterns of Failure After Single-Fraction Stereotactic Body Radiation Therapy (SBRT) for Oligometastases.

Safety, Efficacy, and Patterns of Failure After Single-Fraction Stereotactic Body Radiation Therapy (SBRT) for Oligometastases.

Journal: International journal of radiation oncology, biology, physics

Published: June 27, 2020

Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.

Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.

Journal: European urology oncology

Published: December 29, 2017

68 Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer.

68 Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer.

Journal: Asia-Pacific journal of clinical oncology

Published: September 19, 2017

Showing 1-12 of 17

Last Updated: 09/26/2026